NFKB1 and breast neoplasm: Constitutive activation of nuclear factor κB (NF-κB) is frequently observed in PDAC [23], which suggests that for mt K-ras tumors, zoledronic acid could reduce mTOR resistance and thus enhance the therapeutic efficacy of everolimus, perhaps by inhibiting NF-κB, as previously shown in breast tumors [24].